Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-08-20

FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Diovan HCT (valsartan and hydrochlorothiazide) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Diovan HCT (valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE)